Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
An overview is given on APCCs and recombinant FVIIa for the treatment of bleeding episodes in hemophiliacs with FVIII or FIX inhibitors or in patients with acquired hemophilia. The initial dose of activated plasma-derived PPCs, mainly FEIBA, is up to 100 U/kg body weight, and the maintenance dosage is up to 100 U/kg body weight twice daily. The single dosage of recombinant FVIIa is about 60-90 microg/kg body weight, which has to be repeated every 2 to 6 hours depending on the bleeding situation.
Barthels
M
M
Division of Hematology and Oncology, Medical School Hannover, Germany. mbarthels.hannover@gmx.de
D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use*; D005164:Factor IX / Q000037:antagonists & inhibitors; D005169:Factor VIII / Q000037:antagonists & inhibitors; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D011516:Prothrombin / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety; D014777:Virus Diseases / Q000635:transmission
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX; D015942:Factor VIIa